Role of Combined Anti-PD-1 and Anti-CTLA-4 Therapy in Melanoma Immune Response Background Immune checkpoint inhibitors have made significant progress in clinical oncology, especially anti-PD-1 (anti-programmed death protein 1) and anti-CTLA-4 (anti-cytotoxic T-lymphocyte-associated antigen 4) therapies, which have been proven to induce long-term re...

Exploration of a Chemotherapy and PD-1 Inhibitor Personalized Stratification Strategy Based on Circulating Tumor DNA in Advanced Non-Small Cell Lung Cancer Background and Significance of the Study Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related deaths globally. In the treatment of advanced NSCLC, the combination of immune ...

Clinical Outcomes and Biological Characteristics Study Report for Pancreatic Cancer Patients with KRAS Mutations Research Background and Objective Pancreatic Ductal Adenocarcinoma (PDAC) is predicted to become the second leading cause of cancer death by 2030. Only about 20% of PDAC patients are eligible for resection surgery, thus the five-year sur...

Background and Research Objectives High-Grade Glioma (HGG) is a highly lethal primary brain tumor with a particularly high incidence and mortality rate in children and adolescents. HGG can be further divided into several subtypes, among which Diffuse Hemispheric Glioma, H3G34-mutant (DHG-H3G34), is a rare subtype with poor prognosis, mainly occurri...

Background Glioblastoma (GBM) is a highly aggressive central nervous system malignancy with very poor prognosis, typically associated with short patient survival. Although significant advancements have been made in tumor treatment technologies and strategies in recent years, traditional radiotherapy and chemotherapy still struggle to achieve satisf...